Evidence map›Paper›PMID 29158532›Full record

ArticleScientific reports2017

Recombinant Decorin Fusion Protein Attenuates Murine Abdominal Aortic Aneurysm Formation and Rupture.

Yue Shen, Valerio Russo, Matthew R Zeglinski, Stephanie L Sellers, Zhengguo Wu, Cameron Oram, Stephanie Santacruz, Yulia Merkulova, Christopher Turner, Keerit Tauh and 10 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Biomimetic strategies for the deputization of proteoglycan functions.Frontiers in cell and developmental biology · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Role of Extracellular Matrix and Inflammation in Abdominal Aortic Aneurysm.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 3 countries.

Yue ShenCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Valerio RussoCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Matthew R ZeglinskiInternational Collaboration On Repair Discoveries (ICORD), Vancouver Coastal Health Research Institute and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Stephanie L SellersCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Zhengguo WuImaging Unit, Integrative Oncology Department, BC Cancer Agency Research Centre, Vancouver, BC, Canada.
Cameron OramCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Stephanie SantacruzCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Yulia MerkulovaCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Christopher TurnerCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Keerit TauhInternational Collaboration On Repair Discoveries (ICORD), Vancouver Coastal Health Research Institute and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Hongyan ZhaoCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Tatjana BozinCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Lubos BohunekCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Haishan ZengImaging Unit, Integrative Oncology Department, BC Cancer Agency Research Centre, Vancouver, BC, Canada.
Michael A SeidmanCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
R Chris BleackleyDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.
Bruce M McManusCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Erkki RuoslahtiCancer Research Center, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Tero A H JärvinenFaculty of Medicine & Life Sciences, University of Tampere & Department of Orthopedics & Traumatology, Tampere University Hospital, Tampere, Finland.
David J GranvilleCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. dgranville@icord.org.
International Collaboration On Repair Discoveries · CAUniversity of British Columbia · CAVancouver Coastal Health Research Institute · CABC Cancer Agency · CASt. Paul's Hospital · CADiscovery Institute · USProvidence Health Care · CATampere University Hospital · FIUniversity of Alberta · CA

Funding

CIHR
6 · The paper itself

Abstract

Decorin (DCN) is a small-leucine rich proteoglycan that mediates collagen fibrillogenesis, organization, and tensile strength. Adventitial DCN is reduced in abdominal aortic aneurysm (AAA) resulting in vessel wall instability thereby predisposing the vessel to rupture. Recombinant DCN fusion protein CAR-DCN was engineered with an extended C-terminus comprised of CAR homing peptide that recognizes inflamed blood vessels and penetrates deep into the vessel wall. In the present study, the role of systemically-administered CAR-DCN in AAA progression and rupture was assessed in a murine model. Apolipoprotein E knockout (ApoE-KO) mice were infused with angiotensin II (AngII) for 28 days to induce AAA formation. CAR-DCN or vehicle was administrated systemically until day 15. Mortality due to AAA rupture was significantly reduced in CAR-DCN-treated mice compared to controls. Although the prevalence of AAA was similar between vehicle and CAR-DCN groups, the severity of AAA in the CAR-DCN group was significantly reduced. Histological analysis revealed that CAR-DCN treatment significantly increased DCN and collagen levels within the aortic wall as compared to vehicle controls. Taken together, these results suggest that CAR-DCN treatment attenuates the formation and rupture of Ang II-induced AAA in mice by reinforcing the aortic wall.

Indexed as

Angiotensin IIAnimalsAortic Aneurysm, AbdominalApolipoproteins EDecorinDisease Models, AnimalHumansMiceMice, KnockoutRecombinant ProteinsAngiotensin IIApolipoproteins EDcn protein, mouseDecorinRecombinant Proteins

Identifiers

PMID29158532
PMCPMC5696466
OpenAlexW2769727847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.